Enveric Biosciences, Inc.
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG00P83FXJ0
ENVB
Enveric Biosciences, Inc.
GICS: -
·
Sektor: Healthcare
·
Sub-Sektor: Biotechnology
NAME
Enveric Biosciences, Inc.
ISIN
US29405E2081
TICKER
ENVB
MIC
XNAS
REUTERS
ENVB.OQ
BLOOMBERG
ENVB US
F&G:
35
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Börsenhandel
Warrants
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 31.03.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today provided a corporate update following the filing of its 10-K on Friday March 28, 2025 which reported fin...
Enveric Biosciences
Mo., 17.03.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in BIO-Europe Spring®, which is being held in Milan, Italy, March 17-1...
Enveric Biosciences
Do., 06.03.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced the company will build on its recent business development momentum by soliciting Requests-For-...
Enveric Biosciences
Do., 27.02.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., CEO and Director, has issued a Letter to Shareholders to provide an...
Enveric Biosciences
Di., 25.02.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439 (the ‘439...
Enveric Biosciences
Di., 04.02.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that its wholly-owned subsidiary, Akos Biosciences, Inc. (“Akos”), has entered into two...
Enveric Biosciences
Mo., 03.02.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the closing of its previously announced public offering of an aggregate of 1,666,666 sha...
Enveric Biosciences
Fr., 31.01.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock...
Enveric Biosciences
Do., 30.01.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark O...
Enveric Biosciences
Mo., 06.01.2025
Enveric Biosciences
US29405E2081
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced Joseph Tucker, Ph.D., CEO, will participate in a panel discussion and present at the Sachs Ass...
Enveric Biosciences
Informationen zu Product Placements
SMART * AD
P R O D U C T S U G G E S T I O N S
